

## CONSOLIDATED INCOME STATEMENT

For the year ended 31 December 2004

	Notes	2004 HK\$'000	2003 HK\$'000
Turnover	4	64,179	57,213
Cost of sales		(12,575)	(9,961)
<hr/>			
Gross profit		51,604	47,252
Other operating income	5	3,383	2,370
Marketing, selling and distribution costs		(24,039)	(13,698)
Administrative expenses		(43,355)	(29,378)
Research and development expenditure		(1,500)	(2,247)
Loss on disposal of beneficial rights to a drug under development		(400)	–
(Loss) gain arising on investments in securities	6	(41,293)	36,200
Allowance for doubtful debts	7	(2,391)	(3,956)
<hr/>			
(Loss) profit from operations	8	(57,991)	36,543
Finance costs	10	(289)	(730)
Gain on partial disposal of subsidiaries	11	–	19,127
Loss on disposal of subsidiaries	35	–	(14,948)
Share of loss of an associate		–	(1,433)
<hr/>			
(Loss) profit before taxation		(58,280)	38,559
Income tax expense	12	(2,504)	(7)
<hr/>			
(Loss) profit before minority interests		(60,784)	38,552
Minority interests		(208)	(1,704)
<hr/>			
(Loss) profit for the year		(60,992)	36,848
<hr/>			
(Loss) earnings per share (cents)	13		
– Basic		(2.4)	1.7
<hr/>			
– Diluted		N/A	1.7
<hr/>			